Specific binding of the adenovirus capsid to the nuclear envelope

Juan P. Wisnivesky, Philip L. Leopold, Ronald Crystal

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Adenovirus (Ad) vectors used for gene therapy are efficient in entering the infected cell and targeting their genome to the nucleus. To study the mechanism of the interaction between Ad and the nuclear envelope we have established an in vitro assay using rat liver nuclei incubated with serotype 5 Ad vector. Binding of either fluorophore (Cy3)-labeled Ad5 (Cy3-AdGFP) or [3H]Ad5 was blocked by excess unlabeled Ad5, indicating that the interaction was specific. Binding reached equilibrium within 30 min, exhibited temperature dependence with more binding occurring at 37°C than at 4°C and appeared to be irreversible. Prior treatment of nuclei with glutaraldehyde or proteolysis of nuclei with trypsin inhibited the Cy3-AdGFP association with nuclei, and pretreatment of Cy3-AdGFP with human anti-Ad5 serum, but not naive human serum, inhibited Cy3-AdGFP, suggesting a requirement for direct interaction between Ad5 and nuclei. Addition of excess unlabeled Ad serotype 2 or Ad serotype 7 competed for binding with Cy3-AdGFP, indicating that the capsid determinant of nuclear binding was conserved among group B and C Ad serotypes. These data suggest that the Ad capsid and nuclear envelope contain specific domains that mediate binding of the two entities and that binding mechanisms to the nuclear envelope might be a common final pathway of different Ad serotypes.

Original languageEnglish
Pages (from-to)2187-2195
Number of pages9
JournalHuman Gene Therapy
Volume10
Issue number13
DOIs
Publication statusPublished - 1 Sep 1999
Externally publishedYes

Fingerprint

Capsid
Nuclear Envelope
Adenoviridae
Glutaral
Serum
Genetic Therapy
Trypsin
Proteolysis
Serogroup
Genome
Temperature
Liver

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Specific binding of the adenovirus capsid to the nuclear envelope. / Wisnivesky, Juan P.; Leopold, Philip L.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 10, No. 13, 01.09.1999, p. 2187-2195.

Research output: Contribution to journalArticle

Wisnivesky, Juan P. ; Leopold, Philip L. ; Crystal, Ronald. / Specific binding of the adenovirus capsid to the nuclear envelope. In: Human Gene Therapy. 1999 ; Vol. 10, No. 13. pp. 2187-2195.
@article{41d7bd4f7f854e208892a22175a2e788,
title = "Specific binding of the adenovirus capsid to the nuclear envelope",
abstract = "Adenovirus (Ad) vectors used for gene therapy are efficient in entering the infected cell and targeting their genome to the nucleus. To study the mechanism of the interaction between Ad and the nuclear envelope we have established an in vitro assay using rat liver nuclei incubated with serotype 5 Ad vector. Binding of either fluorophore (Cy3)-labeled Ad5 (Cy3-AdGFP) or [3H]Ad5 was blocked by excess unlabeled Ad5, indicating that the interaction was specific. Binding reached equilibrium within 30 min, exhibited temperature dependence with more binding occurring at 37°C than at 4°C and appeared to be irreversible. Prior treatment of nuclei with glutaraldehyde or proteolysis of nuclei with trypsin inhibited the Cy3-AdGFP association with nuclei, and pretreatment of Cy3-AdGFP with human anti-Ad5 serum, but not naive human serum, inhibited Cy3-AdGFP, suggesting a requirement for direct interaction between Ad5 and nuclei. Addition of excess unlabeled Ad serotype 2 or Ad serotype 7 competed for binding with Cy3-AdGFP, indicating that the capsid determinant of nuclear binding was conserved among group B and C Ad serotypes. These data suggest that the Ad capsid and nuclear envelope contain specific domains that mediate binding of the two entities and that binding mechanisms to the nuclear envelope might be a common final pathway of different Ad serotypes.",
author = "Wisnivesky, {Juan P.} and Leopold, {Philip L.} and Ronald Crystal",
year = "1999",
month = "9",
day = "1",
doi = "10.1089/10430349950017176",
language = "English",
volume = "10",
pages = "2187--2195",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "13",

}

TY - JOUR

T1 - Specific binding of the adenovirus capsid to the nuclear envelope

AU - Wisnivesky, Juan P.

AU - Leopold, Philip L.

AU - Crystal, Ronald

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Adenovirus (Ad) vectors used for gene therapy are efficient in entering the infected cell and targeting their genome to the nucleus. To study the mechanism of the interaction between Ad and the nuclear envelope we have established an in vitro assay using rat liver nuclei incubated with serotype 5 Ad vector. Binding of either fluorophore (Cy3)-labeled Ad5 (Cy3-AdGFP) or [3H]Ad5 was blocked by excess unlabeled Ad5, indicating that the interaction was specific. Binding reached equilibrium within 30 min, exhibited temperature dependence with more binding occurring at 37°C than at 4°C and appeared to be irreversible. Prior treatment of nuclei with glutaraldehyde or proteolysis of nuclei with trypsin inhibited the Cy3-AdGFP association with nuclei, and pretreatment of Cy3-AdGFP with human anti-Ad5 serum, but not naive human serum, inhibited Cy3-AdGFP, suggesting a requirement for direct interaction between Ad5 and nuclei. Addition of excess unlabeled Ad serotype 2 or Ad serotype 7 competed for binding with Cy3-AdGFP, indicating that the capsid determinant of nuclear binding was conserved among group B and C Ad serotypes. These data suggest that the Ad capsid and nuclear envelope contain specific domains that mediate binding of the two entities and that binding mechanisms to the nuclear envelope might be a common final pathway of different Ad serotypes.

AB - Adenovirus (Ad) vectors used for gene therapy are efficient in entering the infected cell and targeting their genome to the nucleus. To study the mechanism of the interaction between Ad and the nuclear envelope we have established an in vitro assay using rat liver nuclei incubated with serotype 5 Ad vector. Binding of either fluorophore (Cy3)-labeled Ad5 (Cy3-AdGFP) or [3H]Ad5 was blocked by excess unlabeled Ad5, indicating that the interaction was specific. Binding reached equilibrium within 30 min, exhibited temperature dependence with more binding occurring at 37°C than at 4°C and appeared to be irreversible. Prior treatment of nuclei with glutaraldehyde or proteolysis of nuclei with trypsin inhibited the Cy3-AdGFP association with nuclei, and pretreatment of Cy3-AdGFP with human anti-Ad5 serum, but not naive human serum, inhibited Cy3-AdGFP, suggesting a requirement for direct interaction between Ad5 and nuclei. Addition of excess unlabeled Ad serotype 2 or Ad serotype 7 competed for binding with Cy3-AdGFP, indicating that the capsid determinant of nuclear binding was conserved among group B and C Ad serotypes. These data suggest that the Ad capsid and nuclear envelope contain specific domains that mediate binding of the two entities and that binding mechanisms to the nuclear envelope might be a common final pathway of different Ad serotypes.

UR - http://www.scopus.com/inward/record.url?scp=0033198897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033198897&partnerID=8YFLogxK

U2 - 10.1089/10430349950017176

DO - 10.1089/10430349950017176

M3 - Article

VL - 10

SP - 2187

EP - 2195

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 13

ER -